NCT04551053 2025-10-02To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)Incyte CorporationPhase 3 Terminated177 enrolled 15 charts
NCT02718300 2024-05-01A Study of INCB050465 in Combination With Ruxolitinib in Subjects With MyelofibrosisIncyte CorporationPhase 2 Terminated74 enrolled 40 charts
NCT02265510 2020-04-17An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated83 enrolled 31 charts
NCT02559492 2019-09-25Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid TumorsIncyte CorporationPhase 1 Terminated142 enrolled